Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera.

Blood advances - 10 May 2022

Guglielmelli Paola, Coltro Giacomo, Mannelli Francesco, Rotunno Giada, Loscocco Giuseppe G, Mannarelli Carmela, Maccari Chiara, Paoli Chiara, Romagnoli Simone, Bartalucci Niccolò, Vannucchi Alessandro M

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Eosinophilic Disorders and Syndromes
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Share to Polycythemia Vera

Share to Primary Myelofibrosis

Share to Repressor Proteins

Share to Thrombocythemia, Essential

Source

Open in PubMed Open full text

Identifiers

PMID: 35020812
DOI: 10.1182/bloodadvances.2021006350
PMCID: PMC9092422

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera.PMID 35020812Read ↗

ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden.Semantic proximity Read ↗

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.Semantic proximity Read ↗

Highly variable mutational profile of ASXL1 in myelofibrosis.Semantic proximity Read ↗

ASXL1 mutations, previous vascular complications and age at diagnosis predict survival in 85 WHO-defined polycythaemia vera patients.Semantic proximity Read ↗

Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential ThrombocytosisSemantic proximity Read ↗

Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progressionSemantic proximity Read ↗

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.Semantic proximity Read ↗

Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.Semantic proximity Read ↗

Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis.Semantic proximity Read ↗

Targeted molecular characterization shows differences between primary and secondary myelofibrosisSemantic proximity Read ↗

ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patientsSemantic proximity Read ↗

U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.